Clinical Trial

Performance Indicators and Impact on the Care Pathway of Sequencing on the SeqOIA and AURAGEN (Seqogen) Platforms for Oncology Patients

Study acronym: SONCO
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 29, 2025 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
As part of the French Genomic Medicine Plan 2025 (FGM), the SeqOIA and AURAGEN platforms were selected to perform high-throughput genomic sequencing. The SONCO (Sequencing Oncology Cohort) project combines their medical and economic evaluations into a single national cohort. Its objective is to assess the impact of genomic sequencing on care pathways and treatment recommendations by collecting indicators related to quality, turnaround time, and patient information. Clinical data are gathered from molecular tumor board reports (via SPICE and HYGEN) and from hospital medical records. This cohort is intended to support public health decision-making and help anticipate the organization of future genomic platforms.
Trial Details
NCT Number NCT07147465
Lead Sponsor Assistance Publique - Hôpitaux de Paris
Collaborators: AuraGen Aesthetics LLC, Centre Leon Berard, Laboratoire SeqOIA, PLAN FRANCE MÉDECINE GÉNOMIQUE 2025
Conditions Cancer, NGS, Tumor, RARE DISEASE
Enrollment 3,149 participants
Start Date 2025-07-01
Primary Completion 2026-07-31 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2025-08-29